Skip to main content

Table 1 Patient characteristics

From: A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia

  Placebo
N= 248
Pregabalin
N= 250
Sex, n (%)   
   Male 31 (12.5) 24 (9.6)
   Female 217 (87.5) 226 (90.4)
Hormonal status, n (%)   
   Premenopausal 133 (61.3) 140 (61.9)
   Postmenopausal 84 (38.7) 86 (38.1)
Age (years)   
   <18, n (%) 0 0
   18 to 44, n (%) 104 (41.9) 101 (40.4)
   45 to 64, n (%) 123 (49.6) 125 (50.0)
   ≥65, n (%) 21 (8.5) 24 (9.6)
   Mean ± SD 46.7 ± 12.6 47.9 ± 12.0
   Range 19, 78 19, 80
Weight, kg   
   Mean ± SD 56.2 ± 9.0 55.5 ± 11.0
   Range 38.9, 90.9 37.2, 104.8
Height, cm   
   Mean ± SD 158.5 ± 6.8 158.3 ± 6.4
   Range 131.9, 179.6 143.8, 176.0
Duration since FM onset, months   
   Mean 62.0 69.6
   Range 0.3, 508.8 0.3, 505.1
  1. FM, fibromyalgia; SD, standard deviation